Wells Fargo Upgrades Aeglea BioTherapeutics to Overweight, Raises Price Target to $2
Wells Fargo analyst Yanan Zhu upgrades Aeglea BioTherapeutics (NASDAQ:AGLE) from Equal-Weight to Overweight and raises the price target from $1.5 to $2.
Related Posts
US Stocks Brace For Another Day In The Red As Rally Loses Steam: Analyst Sees Market Pullback On This Indicator
The stock rally that propelled the S&P 500 and the Dow to record highs last week seems to have stalled, with Fed officials remaining non-committal about rate-cut plans.
Project Management Platform Monday.com Reports Robust Q3 Topline Growth, Stock Climbs
Monday.com Ltd (NASDAQ: MNDY) reported third-quarter (Q3) 2023 revenue growth of 38% Y/Y to $189.2 million, beating the
Agile Therapeutics Announces Extension Granted By Nasdaq Hearings Panel To Regain Compliance Until March 25, 2024; Sees FY23 Revenue $20M-$21M
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of